Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

Darian Andreas, Jeffrey J. Tosoian, Patricia Landis, Sacha Wolf, Stephanie Glavaris, Tamara L. Lotan, Edward M. Schaeffer, Lori J. Sokoll, Ashley E. Ross

Research output: Contribution to journalArticlepeer-review

Abstract

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy of a gentleman undergoing active surveillance leading to reclassification of his disease as high risk prostate cancer.

Original languageEnglish (US)
Pages (from-to)64-66
Number of pages3
JournalUrology Case Reports
Volume7
DOIs
StatePublished - Jul 1 2016

Keywords

  • Active surveillance
  • Biomarkers
  • Prostate biopsy
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer'. Together they form a unique fingerprint.

Cite this